We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Spiramycin/cotrimoxazole versus pyrimethamine/sulfonamide and spiramycin alone for the treatment of toxoplasmosis in pregnancy.
- Authors
Valentini, P; Buonsenso, D; Barone, G; Serranti, D; Calzedda, R; Ceccarelli, M; Speziale, D; Ricci, R; Masini, L
- Abstract
Objective:To compare the effectiviness of spiramycin/cotrimoxazole (Sp/C) versus pyrimethamine/sulfonamide (Pyr/Sul) and spiramycin alone (Spy) on mother-to-child transmission of toxoplasmosis infection in pregnancy.Study design:Retrospective study of pregnant women evaluated for suspected toxoplasmosis between 1992 and 2011.Result:A total of 120 mothers and their 123 newborns were included. Prenatal treatment consisted of spiramycin in 43 mothers (35%), spiramycin/cotrimoxazole in 70 (56.9%) and pyrimethamine/sulfonamide in 10 (8.1%). A trend toward reduction in toxoplasmosis transmission was found when Sp/C was compared with Pyr/Sul and particularly with Spy alone (P=0.014). In particular, Spy increased the risk of congenital infection when compared with Sp/C (odds ratio (OR) 4.368; 95% CI: 1.253 to 15.219), but there was no significant reduction when Sp/C was compared with Pyr/Sul (OR 1.83; 95% CI: 0.184 to 18.274).Conclusion:The treatment based on Sp/C has significant efficacy in reducing maternal-fetal transmission of Toxoplasma gondii when compared with Pyr/Sul and particularly to Spy. Randomized controlled trials would be required.
- Subjects
ANTIFUNGAL agents; CHI-squared test; CONFIDENCE intervals; ENZYME-linked immunosorbent assay; PRENATAL care; TOXOPLASMOSIS; LOGISTIC regression analysis; RETROSPECTIVE studies; DATA analysis software; ODDS ratio; PREGNANCY
- Publication
Journal of Perinatology, 2015, Vol 35, Issue 2, p90
- ISSN
0743-8346
- Publication type
Article
- DOI
10.1038/jp.2014.161